OncoVerity
OncoVerity is a United States-based biotechnology company running 2 late-stage cancer trials of Cusatuzumab in acute myeloid leukaemia.
Overview
OncoVerity, based in Denver, CO, the United States, is a biotechnology company. OncoVerity applies computational tools to clinical and biologic data to develop personalised cancer therapies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Cusatuzumab in acute myeloid leukaemia. The largest, NCT06384261 (A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy), plans to enrol 140 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 1/2 +1
- targets +2
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyOrca Biosystems
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyMiltenyi Biomedicine
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyRyvu Therapeutics
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyEllipses Pharma
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyShenzhen TargetRx
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- TargetCD70
Shares Cusatuzumab, Acute myeloid leukaemia.